Patrick Burnett, MD, PhD, Chief Medical Officer at Arcutis Bioteheraputics, discusses the promise of the company’s roflumilast cream for AD.
Addressing the Unique Challenges of AD Patients
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Patrick Burnett, MD, PhD, Chief Medical Officer at Arcutis Bioteheraputics, discusses the promise of the company’s roflumilast cream for AD.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Practical Dermatology: Atopic Dermatitis
Understanding Disparities in AD
<p>Understanding Disparities in AD</p>
Practical Dermatology: Atopic Dermatitis
DermWire TV Extra: 3-Year Clinical Data on Lebrikizumab
<p>DermWire TV Extra: 3-Year Clinical Data on Lebrikizumab</p>
Practical Dermatology: Atopic Dermatitis
New Drugs Helping AD Catch Up to Psoriasis
<p>New Drugs Helping AD Catch Up to Psoriasis</p>
Practical Dermatology: Atopic Dermatitis
FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
<p>FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)</p>
Practical Dermatology: Atopic Dermatitis
NIH Analysis Examines Association Between AD and Comorbidities
<p>NIH Analysis Examines Association Between AD and Comorbidities</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?